RecruitingNot ApplicableNCT06366425

Screening for Chronic Liver Diseases in General Population

Non-invasive Screening for Chronic Liver Diseases in the General Population. A Prospective Study

Sponsor

University Hospital, Montpellier

Enrollment

260 participants

Start Date

Sep 11, 2024

Study Type

INTERVENTIONAL

Conditions

Fibrosis, Liver

Summary

Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is screening adults in the general population for undetected chronic liver disease using a non-invasive liver scan called FibroScan, targeting people who have risk factors but have never been diagnosed with liver disease. **You may be eligible if...** - You are 40 years or older - You have no known liver conditions - You have at least one risk factor for liver disease, such as risky alcohol use, metabolic syndrome, diabetes, or possible exposure to hepatitis B or C **You may NOT be eligible if...** - You have had a FibroScan done in the last 12 months - You are unable to provide consent or complete the required assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlood sample then fibroscan

The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test. If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan.